Gilead Sciences, Inc. (GILD)
NASDAQ · Health Care · market cap 166.90B
Share price
$170.33
At the last nightly close
Intrinsic value
$136.11
Range $95.85 – $176.92 before any credit for growth. The figure above is $95.85 × 1.42, the credit the franchise record earns.
Margin of safety
-20.1%
($136.11 − $170.33) ÷ $170.33
EV / EBIT
23.3
On the median operating profit of 15 fiscal years through 2025.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.
The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-11-01.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 29.44B | 11.70B | 8.51B | 6.84 | 9.46B |
| 2024-FY | 28.75B | 10.60B | 480.0M | 0.38 | 10.30B |
| 2023-FY | 27.12B | 8.84B | 5.67B | 4.54 | 7.42B |
| 2022-FY | 27.28B | 10.97B | 4.59B | 3.66 | 8.34B |
| 2021-FY | 27.30B | 9.92B | 6.22B | 4.93 | 10.80B |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- GILD Stock Catalyst Calendar: Earnings Dates, Events & Key Triggers | Catacalcatacal.com
- Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting | The Motley Foolfool.com
- Gilead Sciences Beat Q1 2026 Earnings and Raised Guidance. Why Is GILD Stock Still Down 17%? | TIKR.comtikr.com
- Gilead Sciences (GILD) Research Report - StockStorystockstory.org
- Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on GILD.
Run the board on GILD10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.